Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Masaji Tani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1270-6003; OpenAlex author ID A5058284228. Sources: ClinicalTrials.gov.

Their work

Papers
28 (first author 0, last author 9)
Trials
2
Grants
0
Labs led
1
Collaborators
141
Papers, trials and grants by year

2005: 1 trial · 2006: none · 2007: none · 2008: none · 2009: 1 trial · 2010: none · 2011: none · 2012: 3 papers · 2013: none · 2014: 2 papers · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 3 papers · 2023: 3 papers · 2024: 3 papers · 2025: 5 papers · 2026: 1 paper

Papers 28

  1. Painful penile erection as a manifestation of metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s12328-025-02278-w↗
  2. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  3. Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.006↗
  4. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  5. Preoperative Predictive Nomogram (DASINEL Score) for Early Recurrence in Pancreatic Cancer. Last author DOI 10.21873/anticanres.17737↗
  6. Dynamic changes in tumor blood flow during chemotherapy: Implications in customized treatment for pancreatic cancer. Last author DOI 10.3892/ol.2025.15325↗
  7. Clinical impact of the prognostic nutritional index and skeletal muscle index for the incompletion of adjuvant chemotherapy for pancreatic cancer. Last author DOI 10.1016/j.asjsur.2024.10.151↗
  8. Contribution of Immunoscore to Survival Prediction in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21873/anticanres.17277↗
  9. [A Case of Needle Tract Seeding Discovered Three Years after Pancreatic Cancer Surgery and Treated with Local Gastrectomy]. Last author PMID 39948921↗
  10. Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm p… Co-author DOI 10.1002/ags3.12712↗
  11. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  12. Gastrojejunostomy versus endoscopic duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancer: a propensity score… Co-author DOI 10.1007/s00464-022-09685-x↗
  13. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis. Co-author DOI 10.1002/jhbp.1127↗
  14. Estimated tumor blood flow as a predictive imaging indicator of therapeutic response in pancreatic ductal adenocarcinoma: use of three-phase contrast-enhanced … Last author DOI 10.1007/s10147-021-02066-9↗
  15. A High C-Reactive Protein Level on Postoperative Day 7 Is Associated With Poor Survival of Patients With Pancreatic Ductal Adenocarcinoma After Resection. Co-author DOI 10.1177/00031348211023406↗
  16. Optimal Treatment for Octogenarians With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000001579↗
  17. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nat… Co-author DOI 10.1016/j.surg.2019.06.023↗
  18. Vimentin Expression in Tumor Microenvironment Predicts Survival in Pancreatic Ductal Adenocarcinoma: Heterogeneity in Fibroblast Population. Last author DOI 10.1245/s10434-019-07891-x↗
  19. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomize… Co-author DOI 10.1186/s13063-018-3002-z↗
  20. Synchronous primary gallbladder and pancreatic cancer associated with congenital biliary dilatation and pancreaticobiliary maljunction. Last author DOI 10.1186/s40792-017-0388-x↗
  21. Clinicopathological Characteristics of Young Patients With Pancreatic Cancer: An Analysis of Data From Pancreatic Cancer Registry of Japan Pancreas Society. Co-author DOI 10.1097/mpa.0000000000000636↗
  22. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center r… Co-author DOI 10.1016/j.pan.2015.09.008↗
  23. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Co-author DOI 10.1111/cas.12674↗
  24. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.109↗
  25. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-013-2323-6↗
  26. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinic… Co-author DOI 10.1007/s00280-012-1822-1↗
  27. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/j.1349-7006.2012.02214.x↗
  28. [Multidisciplinary therapy for pancreatic cancer - clinical impact for preoperative therapy and peptide vaccine therapy]. Co-author PMID 22421762↗

Trials 2

  1. Evaluation of Isolated Roux-en-Y Reconstruction After Pancreaticoduodenectomy Study chair NCT00915863↗
  2. Randomized Controlled Trial on Pancreatic Stent Tube in Pancreaticoduodenectomy Study director NCT00628186↗

Closest collaborators

The 25 strongest of 141 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromitsu Maehira · 11 shared papers, 2017–2026 · strength 2.04
  2. Haruki Mori · 10 shared papers, 2017–2026 · strength 1.89
  3. Sachiko Kaida · 7 shared papers, 2022–2026 · strength 1.47
  4. Sohei Satoi · 11 shared papers, 2014–2025 · strength 1.11
  5. Hiroki Yamaue · 14 shared papers, 2012–2025 · strength 1.05
  6. Tsutomu Fujii · 7 shared papers, 2016–2025 · strength 0.74
  7. Hidetoshi Eguchi · 7 shared papers, 2016–2025 · strength 0.69
  8. Michiaki Unno · 6 shared papers, 2015–2025 · strength 0.63
  9. Yuichi Nagakawa · 4 shared papers, 2018–2025 · strength 0.54
  10. Satoshi Hirano · 4 shared papers, 2020–2025 · strength 0.51
  11. Tamotsu Kuroki · 5 shared papers, 2016–2025 · strength 0.49
  12. Hisato Igarashi · 5 shared papers, 2016–2025 · strength 0.49
  13. Atsushi Masamune · 5 shared papers, 2016–2025 · strength 0.49
  14. Yoshiki Hirooka · 5 shared papers, 2016–2025 · strength 0.49
  15. Yoshifumi Takeyama · 3 shared papers, 2023–2025 · strength 0.48
  16. Shugo Mizuno · 3 shared papers, 2022–2025 · strength 0.43
  17. Toshiki Rikiyama · 3 shared papers, 2022–2025 · strength 0.43
  18. Itaru Endo · 3 shared papers, 2022–2025 · strength 0.43
  19. Takao Itoi · 5 shared papers, 2012–2025 · strength 0.42
  20. Ippei Matsumoto · 4 shared papers, 2015–2023 · strength 0.39
  21. Tomohisa Yamamoto · 3 shared papers, 2020–2025 · strength 0.37
  22. Masayuki Sho · 4 shared papers, 2015–2023 · strength 0.36
  23. Toru Furukawa · 2 shared papers, 2025 · strength 0.35
  24. Shinichi Egawa · 4 shared papers, 2014–2025 · strength 0.34
  25. Takahiro Akahori · 3 shared papers, 2015–2025 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.